PMID- 37904705
OWN - NLM
STAT- MEDLINE
DCOM- 20231102
LR  - 20231108
IS  - 2050-4527 (Electronic)
IS  - 2050-4527 (Linking)
VI  - 11
IP  - 10
DP  - 2023 Oct
TI  - Combined use of total glucosides of paeony and hydroxychloroquine in primary 
      Sjogren's syndrome: A systematic review.
PG  - e1044
LID - 10.1002/iid3.1044 [doi]
LID - e1044
AB  - OBJECTIVE: To assess the effectiveness and safety of the total glucosides of 
      paeony (TGP) combined with hydroxychloroquine (HCQ) on the treatment of primary 
      Sjogren's syndrome (pSS) by conducting a meta-analysis. METHODS: Eight databases 
      were searched for randomized controlled trials (RCTs) reporting the use of TGP 
      combined with HCQ for pSS, which are before May 10, 2022. Meta-analyses were 
      performed on disappeared clinical symptoms (dry mouth and dry eyes), Schirmer's 
      test, saliva flow test, erythrocyte sedimentation rate (ESR), index of 
      immunoglobulin G (IgG), immunoglobulin M (IgM), immunoglobulin A (IgA), and 
      adverse events (AEs). The Revman 5.4 software was used for this meta-analysis. 
      RESULTS: Seven RCTs which included 632 participants were identified. The pooled 
      results showed significant differences in clinical symptoms disappear (dry mouth 
      and dry eyes) (p = .0004), IgM (p < .00001), IgA (p < .00001), salivary flow rate 
      (p < .00001) and Schirmer's test (p = .02) in the comparison of TGP combined with 
      HCQ and HCQ alone. For the IgG and ESR, both pooled and subgroup analyses showed 
      that TGP + HCQ was superior to HCQ alone. For the safety analysis, no significant 
      differences in AEs (p = .39) was revealed. The more frequently seen adverse 
      reactions were diarrhea, vomit and there was no severe adverse events were 
      reported in TGP + HCQ group. CONCLUSION: Therefore, TGP + HCQ can be considered 
      to be a potentially valid and safe combination for the treatment of pSS in the 
      clinic.
CI  - (c) 2023 The Authors. Immunity, Inflammation and Disease published by John Wiley & 
      Sons Ltd.
FAU - Zhang, Aiping
AU  - Zhang A
AUID- ORCID: 0009-0000-9969-9437
AD  - Hangzhou Traditional Chinese Medicine Hospital Affiliated to Zhejiang Chinese 
      Medical University, Hangzhou, China.
FAU - Chen, Shilei
AU  - Chen S
AD  - Zhuji Maternal and Child Health Hospital, Shaoxing, China.
FAU - Lin, Riyang
AU  - Lin R
AD  - Hangzhou Traditional Chinese Medicine Hospital Affiliated to Zhejiang Chinese 
      Medical University, Hangzhou, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
PL  - England
TA  - Immun Inflamm Dis
JT  - Immunity, inflammation and disease
JID - 101635460
RN  - 4QWG6N8QKH (Hydroxychloroquine)
RN  - 0 (Glucosides)
RN  - 0 (Immunoglobulin A)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Immunoglobulin M)
SB  - IM
MH  - Humans
MH  - Hydroxychloroquine/adverse effects
MH  - *Sjogren's Syndrome/drug therapy/diagnosis
MH  - *Paeonia
MH  - Glucosides/adverse effects
MH  - *Dry Eye Syndromes/drug therapy
MH  - Immunoglobulin A
MH  - Immunoglobulin G
MH  - Immunoglobulin M/therapeutic use
PMC - PMC10587734
OTO - NOTNLM
OT  - hydroxychloroquine
OT  - primary Sjogren's syndrome
OT  - total glucosides of paeony
COIS- The authors declare no conflict of interest.
EDAT- 2023/10/31 06:42
MHDA- 2023/11/02 12:44
PMCR- 2023/10/20
CRDT- 2023/10/31 03:49
PHST- 2023/09/14 00:00 [revised]
PHST- 2023/05/07 00:00 [received]
PHST- 2023/09/30 00:00 [accepted]
PHST- 2023/11/02 12:44 [medline]
PHST- 2023/10/31 06:42 [pubmed]
PHST- 2023/10/31 03:49 [entrez]
PHST- 2023/10/20 00:00 [pmc-release]
AID - IID31044 [pii]
AID - 10.1002/iid3.1044 [doi]
PST - ppublish
SO  - Immun Inflamm Dis. 2023 Oct;11(10):e1044. doi: 10.1002/iid3.1044.